Stocks
Atreca, Inc.BCEL
NASDAQHealthcareBiotechnology$0.09-1.32%
A clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapeutics for cancer. The company's pipeline includes T-cell engaging bispecific antibodies targeting solid tumors, attracting investor interest in its potential oncology treatments despite its micro-cap status.
Market Cap: $3.6M52W Range: $0.05 – $1.20
Congressional Interest in Atreca, Inc. (BCEL)
1 member of Congress has disclosed 2 trades in Atreca, Inc. (BCEL), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
1
Buys
1
Sells
1
Who in Congress Is Trading BCEL?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-11-08 | Christopher L. Jacobs | sell | $1K – $15K |
| 2022-06-16 | Christopher L. Jacobs | buy | $15K – $50K |